Conclusions
The AGREE II assessment of the four included SCD in pregnancy CPGs
revealed methodological shortcomings in several domains. We recommend
several areas for improvement for future CPGs, using the AGREE II
criteria and the RCOG and NICE CPGs as models. The NICE 2016, RCOG 2018,
followed by the NHLBI 2014 CPGs, showed the highest quality and were
strongly recommended in the present evaluation. This critical appraisal
highlights the importance of quality assessment of CPGs by clinicians to
ensure the transparency and strength of the CPG development process
according to international CPG standards and to support the provision of
best practice for pregnant women with SCD. We recommend incorporating
the AGREE II appraisal of CPGs in the capacity building of Obstetricians
and Gynecologists and Hematologists.